These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 19301566

  • 1. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
    Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ.
    J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
    [Abstract] [Full Text] [Related]

  • 2. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 3. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

  • 4. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G.
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [Abstract] [Full Text] [Related]

  • 5. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
    Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
    [Abstract] [Full Text] [Related]

  • 6. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 7. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 8. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 9. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery.
    Rebarber A, Istwan NB, Russo-Stieglitz K, Cleary-Goldman J, Rhea DJ, Stanziano GJ, Saltzman DH.
    Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346
    [Abstract] [Full Text] [Related]

  • 10. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
    Rebarber A, Fox NS, Klauser CK, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
    [Abstract] [Full Text] [Related]

  • 11. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K.
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [Abstract] [Full Text] [Related]

  • 12. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
    [Abstract] [Full Text] [Related]

  • 13. 17 hydroxyprogesterone for the prevention of preterm delivery.
    Meis PJ, Society for Maternal-Fetal Medicine.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
    [Abstract] [Full Text] [Related]

  • 14. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
    How HY, Barton JR, Istwan NB, Rhea DJ, Stanziano GJ.
    Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
    [Abstract] [Full Text] [Related]

  • 15. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, Perrotin F, Bohec C, Connan L, Vayssière C, Langer B, Mantel A, Azimi S, Porcher R, Azria E, Groupe De Recherche En Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
    [Abstract] [Full Text] [Related]

  • 16. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 17. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ.
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [Abstract] [Full Text] [Related]

  • 18. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [Abstract] [Full Text] [Related]

  • 19. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S, Wallace L, Alexander J, Istwan N.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [Abstract] [Full Text] [Related]

  • 20. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B, Poole-Yaeger A, Istwan N, Stanziano G, Rhea D, Mason M.
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.